Pediatric Bacterial Meningitis Surveillance in Nigeria From 2010 to 2016, Prior to and During the Phased Introduction of the 10-Valent Pneumococcal Conjugate Vaccine.
Child, Preschool
Cost of Illness
Female
Haemophilus influenzae
/ classification
Hospitalization
/ statistics & numerical data
Humans
Infant
Infant, Newborn
Longitudinal Studies
Male
Meningitis, Bacterial
/ epidemiology
Neisseria meningitidis
/ classification
Nigeria
Pneumococcal Vaccines
/ administration & dosage
Sentinel Surveillance
Serogroup
Streptococcus pneumoniae
/ classification
Nigeria
meningitis
meningococcus
neumococcus
pediatric
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 09 2019
05 09 2019
Historique:
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
29
9
2020
Statut:
ppublish
Résumé
Historically, Nigeria has experienced large bacterial meningitis outbreaks with high mortality in children. Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae are major causes of this invasive disease. In collaboration with the World Health Organization, we conducted longitudinal surveillance in sentinel hospitals within Nigeria to establish the burden of pediatric bacterial meningitis (PBM). From 2010 to 2016, cerebrospinal fluid was collected from children <5 years of age, admitted to 5 sentinel hospitals in 5 Nigerian states. Microbiological and latex agglutination techniques were performed to detect the presence of pneumococcus, meningococcus, and H. influenzae. Species-specific polymerase chain reaction and serotyping/grouping were conducted to determine specific causative agents of PBM. A total of 5134 children with suspected meningitis were enrolled at the participating hospitals; of these 153 (2.9%) were confirmed PBM cases. The mortality rate for those infected was 15.0% (23/153). The dominant pathogen was pneumococcus (46.4%: 71/153) followed by meningococcus (34.6%: 53/153) and H. influenzae (19.0%: 29/153). Nearly half the pneumococcal meningitis cases successfully serotyped (46.4%: 13/28) were caused by serotypes that are included in the 10-valent pneumococcal conjugate vaccine. The most prevalent meningococcal and H. influenzae strains were serogroup W and serotype b, respectively. Vaccine-type bacterial meningitis continues to be common among children <5 years in Nigeria. Challenges with vaccine introduction and coverage may explain some of these finding. Continued surveillance is needed to determine the distribution of serotypes/groups of meningeal pathogens across Nigeria and help inform and sustain vaccination policies in the country.
Sections du résumé
BACKGROUND
Historically, Nigeria has experienced large bacterial meningitis outbreaks with high mortality in children. Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae are major causes of this invasive disease. In collaboration with the World Health Organization, we conducted longitudinal surveillance in sentinel hospitals within Nigeria to establish the burden of pediatric bacterial meningitis (PBM).
METHODS
From 2010 to 2016, cerebrospinal fluid was collected from children <5 years of age, admitted to 5 sentinel hospitals in 5 Nigerian states. Microbiological and latex agglutination techniques were performed to detect the presence of pneumococcus, meningococcus, and H. influenzae. Species-specific polymerase chain reaction and serotyping/grouping were conducted to determine specific causative agents of PBM.
RESULTS
A total of 5134 children with suspected meningitis were enrolled at the participating hospitals; of these 153 (2.9%) were confirmed PBM cases. The mortality rate for those infected was 15.0% (23/153). The dominant pathogen was pneumococcus (46.4%: 71/153) followed by meningococcus (34.6%: 53/153) and H. influenzae (19.0%: 29/153). Nearly half the pneumococcal meningitis cases successfully serotyped (46.4%: 13/28) were caused by serotypes that are included in the 10-valent pneumococcal conjugate vaccine. The most prevalent meningococcal and H. influenzae strains were serogroup W and serotype b, respectively.
CONCLUSIONS
Vaccine-type bacterial meningitis continues to be common among children <5 years in Nigeria. Challenges with vaccine introduction and coverage may explain some of these finding. Continued surveillance is needed to determine the distribution of serotypes/groups of meningeal pathogens across Nigeria and help inform and sustain vaccination policies in the country.
Identifiants
pubmed: 31505626
pii: 5561327
doi: 10.1093/cid/ciz474
pmc: PMC6736152
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S81-S88Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Trop Med Int Health. 2000 Mar;5(3):207-13
pubmed: 10747284
Afr Health. 1997 Nov;20(1):13, 15
pubmed: 12348371
Diagn Microbiol Infect Dis. 2004 Aug;49(4):249-54
pubmed: 15313529
Bull World Health Organ. 2004 Dec;82(12):914-22
pubmed: 15654405
J Trop Pediatr. 2008 Apr;54(2):83-6
pubmed: 18292101
Int J Health Geogr. 2008 Jul 02;7:34
pubmed: 18597686
Emerg Infect Dis. 2008 Jul;14(7):1089-96
pubmed: 18598630
J Infect Dev Ctries. 2008 Apr 01;2(2):112-5
pubmed: 19738334
Clin Microbiol Rev. 2010 Jul;23(3):467-92
pubmed: 20610819
Lancet. 2011 Dec 3;378(9807):1962-73
pubmed: 21492929
J R Soc Interface. 2012 Dec 05;10(79):20120814
pubmed: 23221989
J Clin Microbiol. 2013 Feb;51(2):647-52
pubmed: 23224094
BMC Infect Dis. 2013 Jan 22;13:26
pubmed: 23339355
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1159-62
pubmed: 25503919
PLoS One. 2016 Feb 01;11(2):e0147765
pubmed: 26829233
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
Vaccine. 2016 May 23;34(24):2722-8
pubmed: 27108191
PLoS One. 2016 Apr 27;11(4):e0153003
pubmed: 27119988
PLoS Curr. 2016 Jul 07;8:null
pubmed: 27508101
Lancet Infect Dis. 2017 Aug;17(8):789-790
pubmed: 28545720
Sci Rep. 2017 Aug 15;7(1):8127
pubmed: 28811633
PLoS One. 2018 Feb 21;13(2):e0193263
pubmed: 29466459
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Am J Clin Pathol. 1984 May;81(5):651-4
pubmed: 6720631
Pediatr Infect Dis J. 1993 Jan;12(1):37-41
pubmed: 8417424